Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. / Kiga, Kotaro; Tan, Xin-Ee; Ibarra-Chávez, Rodrigo; Watanabe, Shinya; Aiba, Yoshifumi; Sato’o, Yusuke; Li, Feng-Yu; Sasahara, Teppei; Cui, Bintao; Kawauchi, Moriyuki; Boonsiri, Tanit; Thitiananpakorn, Kanate; Taki, Yusuke; Azam, Aa Haeruman; Suzuki, Masato; Penadés, José R; Cui, Longzhu.

In: Nature Communications, Vol. 11, 2934, 2020.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Kiga, K, Tan, X-E, Ibarra-Chávez, R, Watanabe, S, Aiba, Y, Sato’o, Y, Li, F-Y, Sasahara, T, Cui, B, Kawauchi, M, Boonsiri, T, Thitiananpakorn, K, Taki, Y, Azam, AH, Suzuki, M, Penadés, JR & Cui, L 2020, 'Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria', Nature Communications, vol. 11, 2934. https://doi.org/10.1038/s41467-020-16731-6

APA

Kiga, K., Tan, X-E., Ibarra-Chávez, R., Watanabe, S., Aiba, Y., Sato’o, Y., Li, F-Y., Sasahara, T., Cui, B., Kawauchi, M., Boonsiri, T., Thitiananpakorn, K., Taki, Y., Azam, A. H., Suzuki, M., Penadés, J. R., & Cui, L. (2020). Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. Nature Communications, 11, [2934]. https://doi.org/10.1038/s41467-020-16731-6

Vancouver

Kiga K, Tan X-E, Ibarra-Chávez R, Watanabe S, Aiba Y, Sato’o Y et al. Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. Nature Communications. 2020;11. 2934. https://doi.org/10.1038/s41467-020-16731-6

Author

Kiga, Kotaro ; Tan, Xin-Ee ; Ibarra-Chávez, Rodrigo ; Watanabe, Shinya ; Aiba, Yoshifumi ; Sato’o, Yusuke ; Li, Feng-Yu ; Sasahara, Teppei ; Cui, Bintao ; Kawauchi, Moriyuki ; Boonsiri, Tanit ; Thitiananpakorn, Kanate ; Taki, Yusuke ; Azam, Aa Haeruman ; Suzuki, Masato ; Penadés, José R ; Cui, Longzhu. / Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. In: Nature Communications. 2020 ; Vol. 11.

Bibtex

@article{9bc1ada3f7944f6789ad62eb8ac329d9,
title = "Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria",
abstract = "Emergence of antimicrobial-resistant bacteria is an increasingly serious threat to global health, necessitating the development of innovative antimicrobials. We established a series of CRISPR-Cas13a-based antimicrobials, termed PhagoCas13a(s), capable of sequence-specific killing of carbapenem-resistant Escherichia coli and methicillin-resistant Staphylococcus aureus through promiscuous RNA cleavage after recognizing corresponding antimicrobial resistance genes. PhagoCas13a constructs were generated by packaging CRISPR-Cas13a into a bacteriophage to target antimicrobial resistance genes. Contrary to Cas9-based antimicrobials that lack bacterial killing capacity when the target genes are located on a plasmid, the PhagoCas13a(s) exhibited strong bacterial killing activities upon recognizing target genes regardless of their location. The antimicrobials{\textquoteright} treatment efficacy was confirmed using a Galleria mellonella larvae model. Further, we demonstrated that the PhagoCas13a(s) can assist in bacterial gene detection without employing nucleic acid amplification and optical devices. One Sentence Summary Novel gene-specific antimicrobials capable of killing drug-resistant bacteria and applicable to detect bacterial genes were developed.",
author = "Kotaro Kiga and Xin-Ee Tan and Rodrigo Ibarra-Ch{\'a}vez and Shinya Watanabe and Yoshifumi Aiba and Yusuke Sato{\textquoteright}o and Feng-Yu Li and Teppei Sasahara and Bintao Cui and Moriyuki Kawauchi and Tanit Boonsiri and Kanate Thitiananpakorn and Yusuke Taki and Azam, {Aa Haeruman} and Masato Suzuki and Penad{\'e}s, {Jos{\'e} R} and Longzhu Cui",
year = "2020",
doi = "10.1038/s41467-020-16731-6",
language = "English",
volume = "11",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria

AU - Kiga, Kotaro

AU - Tan, Xin-Ee

AU - Ibarra-Chávez, Rodrigo

AU - Watanabe, Shinya

AU - Aiba, Yoshifumi

AU - Sato’o, Yusuke

AU - Li, Feng-Yu

AU - Sasahara, Teppei

AU - Cui, Bintao

AU - Kawauchi, Moriyuki

AU - Boonsiri, Tanit

AU - Thitiananpakorn, Kanate

AU - Taki, Yusuke

AU - Azam, Aa Haeruman

AU - Suzuki, Masato

AU - Penadés, José R

AU - Cui, Longzhu

PY - 2020

Y1 - 2020

N2 - Emergence of antimicrobial-resistant bacteria is an increasingly serious threat to global health, necessitating the development of innovative antimicrobials. We established a series of CRISPR-Cas13a-based antimicrobials, termed PhagoCas13a(s), capable of sequence-specific killing of carbapenem-resistant Escherichia coli and methicillin-resistant Staphylococcus aureus through promiscuous RNA cleavage after recognizing corresponding antimicrobial resistance genes. PhagoCas13a constructs were generated by packaging CRISPR-Cas13a into a bacteriophage to target antimicrobial resistance genes. Contrary to Cas9-based antimicrobials that lack bacterial killing capacity when the target genes are located on a plasmid, the PhagoCas13a(s) exhibited strong bacterial killing activities upon recognizing target genes regardless of their location. The antimicrobials’ treatment efficacy was confirmed using a Galleria mellonella larvae model. Further, we demonstrated that the PhagoCas13a(s) can assist in bacterial gene detection without employing nucleic acid amplification and optical devices. One Sentence Summary Novel gene-specific antimicrobials capable of killing drug-resistant bacteria and applicable to detect bacterial genes were developed.

AB - Emergence of antimicrobial-resistant bacteria is an increasingly serious threat to global health, necessitating the development of innovative antimicrobials. We established a series of CRISPR-Cas13a-based antimicrobials, termed PhagoCas13a(s), capable of sequence-specific killing of carbapenem-resistant Escherichia coli and methicillin-resistant Staphylococcus aureus through promiscuous RNA cleavage after recognizing corresponding antimicrobial resistance genes. PhagoCas13a constructs were generated by packaging CRISPR-Cas13a into a bacteriophage to target antimicrobial resistance genes. Contrary to Cas9-based antimicrobials that lack bacterial killing capacity when the target genes are located on a plasmid, the PhagoCas13a(s) exhibited strong bacterial killing activities upon recognizing target genes regardless of their location. The antimicrobials’ treatment efficacy was confirmed using a Galleria mellonella larvae model. Further, we demonstrated that the PhagoCas13a(s) can assist in bacterial gene detection without employing nucleic acid amplification and optical devices. One Sentence Summary Novel gene-specific antimicrobials capable of killing drug-resistant bacteria and applicable to detect bacterial genes were developed.

U2 - 10.1038/s41467-020-16731-6

DO - 10.1038/s41467-020-16731-6

M3 - Journal article

C2 - 32523110

VL - 11

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 2934

ER -

ID: 241528669